Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.
This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report on digital innovation from Japanese drugmakers.
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.
Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.
One pharmacy director would like to see a lot more comparative data about new therapies.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
- Why President Trump Won't Overhaul the FDA
- Five things for pharma marketers to know: Monday, February 27, 2017
- Guidemark Health's Sophy Regelous on why small budgets are increasing
- What uncertainty? 72% of health marketers say 2017 budgets are up
- Publicis Health formalizes new name, promotes 3 execs